Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

Abstract:

INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, and despite research efforts, the underlying mechanisms of AD and optimal treatment targets have not been fully elucidated. Amyloid and tau are key pathological markers of AD with ongoing trials targeting both. However, there are also many trials at various stages of development that primarily target other markers and processes implicated in the disease, which are now being investigated. Areas covered: This review summarizes current treatment approaches for AD and explores both repositioned and novel therapies that target non amyloid and non tau mechanisms that are in the clinical trials pipeline. This includes treatments for cognitive and neuropsychiatric symptoms and potentially disease modifying therapies. The studies included in this review have been obtained from searches of PubMed and clinical trials databases. Expert commentary: There is a renewed energy in identifying better treatments for behavioural symptoms of AD using both novel drugs and repositioning existing drugs. Lack of success in clinical trials of drugs targeting amyloid and tau have led to a surge in targeting alternative mechanisms. Progress in the development of biomarkers will provide further tools for clinical trials of potential therapeutics for both symptomatic treatment and disease modification in AD.

journal_name

Expert Rev Neurother

authors

Khan A,Corbett A,Ballard C

doi

10.1080/14737175.2017.1326818

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

683-695

issue

7

eissn

1473-7175

issn

1744-8360

journal_volume

17

pub_type

杂志文章,评审
  • Effects of surgical resection and adjuvant therapy on pediatric intracranial ependymomas.

    abstract::The optimal therapy of pediatric ependymomas is controversial. The benefit of surgical resection is widely accepted, but the role of adjuvant therapy is subject to debate. Due to the relatively low survival rates of ependymoma patients, as well as the tumor's high recurrence rates, further research into the efficacy o...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.4.465

    authors: Krieger MD,Bowen IE

    更新日期:2005-07-01 00:00:00

  • Systemic thrombolytic therapy of acute ischemic stroke with rtPA.

    abstract::Systemic thrombolysis with recombinant tissue plasminogen activator is the first therapy proven to be effective in acute ischemic stroke. Nevertheless, its efficacy and feasibility are still a matter of debate. Much of this debate derives from uncertainties regarding patient eligibility and problems implementing this ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.2.187

    authors: Koennecke HC

    更新日期:2002-03-01 00:00:00

  • Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.

    abstract::Parkinson's disease (PD) is characterized clinically by rest tremor, rigidity, bradykinesia and pathologically by degeneration of nigrostriatal dopamine neurons. Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of PD. Ongoing clinical and preclinical ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.868306

    authors: Ramirez-Zamora A,Molho E

    更新日期:2014-01-01 00:00:00

  • New therapeutics in spine metastases.

    abstract::The number of patients who will develop metastatic spinal tumors is estimated to be between 5 and 10% of all cancer patients. As the therapy for systemic cancer improves, the number of patients developing symptomatic spinal tumors that require local therapy will increase. Over the last 10 years there has been a dramat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.6.831

    authors: Bilsky MH

    更新日期:2005-11-01 00:00:00

  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?

    abstract::Braak's proposal that, in patients with Parkinson's disease, Lewy bodies and neurites progressively invade the brain through regions connected to autonomic and olfactory centers remains contentious. Confounding factors include the lack of an in vivo marker to examine the progression of Lewy pathology, the retrospectiv...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.47

    authors: Halliday G,McCann H,Shepherd C

    更新日期:2012-06-01 00:00:00

  • No evidence of disease activity in multiple sclerosis patients.

    abstract:INTRODUCTION:Multiple Sclerosis is a chronic inflammatory demyelinating disease that affects 2.5 million people in the world. NEDA (No evidence of disease Activity) -4 is a new concept related to absence of disease activity in the context of MS. It takes into account the following four parameters: relapses; disability ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1202763

    authors: Matta AP,Nascimento OJ,Ferreira AC,Magalhães TN,Benevides TP,Kirmse A,Dib JG,Cal H,Orsini M,Araujo LM

    更新日期:2016-11-01 00:00:00

  • Technology-based assessment of motor and nonmotor phenomena in Parkinson disease.

    abstract:INTRODUCTION:The increasing development and availability of portable and wearable technologies is rapidly expanding the field of technology-based objective measures (TOMs) in neurological disorders, including Parkinson disease (PD). Substantial challenges remain in the recognition of disease phenomena relevant to patie...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2018.1530593

    authors: Merola A,Sturchio A,Hacker S,Serna S,Vizcarra JA,Marsili L,Fasano A,Espay AJ

    更新日期:2018-11-01 00:00:00

  • Acetyl-l-carnitine as a possible therapy for Alzheimer's disease.

    abstract::Alterations have been demonstrated in membrane phospholipid metabolism in Alzheimer's disease. Alterations in membrane phospholipid metabolite levels have been observed by 31P magnetic resonance spectroscopy 4 years before onset of cognitive changes. Implications of phospholipid membrane changes in Alzheimer's disease...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.5.647

    authors: Pettegrew JW,McClure RJ

    更新日期:2002-09-01 00:00:00

  • Craniomandibular muscles, intraoral orthoses and migraine.

    abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.3.371

    authors: Shevel E

    更新日期:2005-05-01 00:00:00

  • The emerging role of psilocybin and MDMA in the treatment of mental illness.

    abstract:INTRODUCTION:Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive, and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Inde...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1826931

    authors: Gill H,Gill B,Chen-Li D,El-Halabi S,Rodrigues NB,Cha DS,Lipsitz O,Lee Y,Rosenblat JD,Majeed A,Mansur RB,Nasri F,Ho R,McIntyre RS

    更新日期:2020-12-01 00:00:00

  • Internet-supported versus face-to-face cognitive behavior therapy for depression.

    abstract::Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.2015.1125783

    authors: Andersson G,Topooco N,Havik O,Nordgreen T

    更新日期:2016-01-01 00:00:00

  • Poor insight into schizophrenia: contributing factors, consequences and emerging treatment approaches.

    abstract::Poor insight or unawareness of illness has been commonly observed in schizophrenia and has been long recognized as a potent barrier to treatment adherence and a risk factor for a range of poorer outcomes. Paradoxically, the achievement of insight often poses a different set of problems including depression and low sel...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.811150

    authors: Lysaker PH,Vohs J,Hillis JD,Kukla M,Popolo R,Salvatore G,Dimaggio G

    更新日期:2013-07-01 00:00:00

  • Metabolic treatments of migraine.

    abstract::Introduction: Most preventive migraine treatments modify the brain's excitation/inhibition balance and/or serotonin metabolism, which likely accounts for their unfavorable adverse effect profile. Novel biological therapies blocking CGRP transmission are effective and better tolerated, but they are expensive and may no...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1729130

    authors: Lisicki M,Schoenen J

    更新日期:2020-03-01 00:00:00

  • Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.

    abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.988709

    authors: Prakash A,Kalra J,Mani V,Ramasamy K,Majeed AB

    更新日期:2015-01-01 00:00:00

  • Therapeutic options for cervicogenic headache.

    abstract::The term cervicogenic headache (CeH) describes a syndrome originating from the cervical spine. There are a variety of therapeutic approaches used for the management of CeH, but scientific evidence of their effectiveness is scarce. No medication drug has proven to be effective. The evidence for greater occipital nerve ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.863710

    authors: Fernández-de-las-Peñas C,Cuadrado ML

    更新日期:2014-01-01 00:00:00

  • New concepts in the early and preclinical detection of Parkinson's disease: therapeutic implications.

    abstract::Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.12.144

    authors: Akhtar RS,Stern MB

    更新日期:2012-12-01 00:00:00

  • Blood pressure control and prevention of stroke.

    abstract::Hypertension is an important risk factor for stroke. The latter results in disability and premature death and represents a major public health problem. Various studies have established a strong relationship between increasing blood pressure and stroke risk, as well as clear evidence of a reduction in the incidence of ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.6.2.203

    authors: Karthikeyan VJ,Lip GY

    更新日期:2006-02-01 00:00:00

  • Twenty-five years of evolution of standard diagnostic criteria for neurocysticercosis. How have they impacted diagnosis and patient outcomes?

    abstract::Introduction: Neurocysticercosis (NCC) is the most common helminthic infection of the central nervous system and a global public health problem. However, its diagnosis is complicated since histological demonstration of the parasite is often not feasible, clinical manifestations are nonspecific, most neuroimaging findi...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1707667

    authors: Del Brutto OH

    更新日期:2020-02-01 00:00:00

  • Intensive voice treatment in Parkinson's disease: Lee Silverman Voice Treatment.

    abstract::Advances in neuroscience have led to an expanded and improved understanding of neurobiological changes associated with rehabilitation and exercise in Parkinson's disease (PD). This knowledge has led to a direct clinical impact of increased referral for early and continuous exercise programs for individuals with PD (ph...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.43

    authors: Sapir S,Ramig LO,Fox CM

    更新日期:2011-06-01 00:00:00

  • Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.

    abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1621750

    authors: Kuo YC,Rajesh R

    更新日期:2019-07-01 00:00:00

  • Health economic evaluation: why? When? How?

    abstract::Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.865872

    authors: Kobelt G

    更新日期:2013-12-01 00:00:00

  • Complementary and alternative medicine therapies in mood disorders.

    abstract::This article reviews the potential uses of complementary and alternative medicine (CAM) techniques for individuals with mood disorders. Mood disorders are among the most prevalent mental health issues today and there are many approaches towards their management. While many different types of medication are available, ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.77

    authors: Moss AS,Monti DA,Amsterdam JD,Newberg AB

    更新日期:2011-07-01 00:00:00

  • Improving understanding of trigger points and widespread pressure pain sensitivity in tension-type headache patients: clinical implications.

    abstract:INTRODUCTION:The underlying etiology of tension type headache (TTH) is not understood. The current paper highlights the etiologic role of muscle trigger points (TrPs) to the development and maintenance of central sensitization in TTH and its clinical repercussion for proper management of these patients. Areas covered: ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1359088

    authors: Fernández-De-Las-Peñas C,Arendt-Nielsen L

    更新日期:2017-09-01 00:00:00

  • Treating multiple sclerosis with monoclonal antibodies: a 2013 update.

    abstract::The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.13.17

    authors: Deiß A,Brecht I,Haarmann A,Buttmann M

    更新日期:2013-03-01 00:00:00

  • Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

    abstract::Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1028370

    authors: Rizzo R,Martino D

    更新日期:2015-04-01 00:00:00

  • Light and chemical control of neuronal circuits: possible applications in neurotherapy.

    abstract::Millions of people worldwide suffer from diseases that result from a failure of central pathways to regulate behavioral and physiological processes. Advances in genetics and pharmacology have already allowed us to appreciate that rather than this dysregulation being systemic throughout the brain, it is usually rooted ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.948850

    authors: Whittle AJ,Walsh J,de Lecea L

    更新日期:2014-09-01 00:00:00

  • Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.

    abstract::Lennox-Gastaut syndrome is a relatively rare epilepsy syndrome that usually begins in early-mid childhood and is characterized by multiple seizure types, particularly generalized seizures, which are often resistant to antiepileptic drug medication. Rufinamide is a new antiepileptic drug approved as adjunctive therapy ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.51

    authors: Ferrie CD

    更新日期:2010-06-01 00:00:00

  • Cognitive-behavioral therapy for bipolar disorder.

    abstract::Bipolar disorder is one of the most serious and prevalent psychiatric disorders. The aim of the present article is to review the efficiency of cognitive-behavioral therapy (CBT) for bipolar patients. Some studies show consistent evidence that cognitive therapy, concomitant to psycho-education and pharmacological treat...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.75

    authors: da Costa RT,Rangé BP,Malagris LE,Sardinha A,de Carvalho MR,Nardi AE

    更新日期:2010-07-01 00:00:00

  • Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

    abstract::Median survival of patients with malignant glioma (MG) from time of diagnosis is approximately 1 year, despite surgery, irradiation and conventional chemotherapy. Improving patient outcome relies on our ability to develop more effective therapies that are directed against the unique molecular aberrations within a pati...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.116

    authors: Thaker NG,Pollack IF

    更新日期:2009-12-01 00:00:00